Compare LXU & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXU | LXEO |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.6M | 663.5M |
| IPO Year | 1969 | 2023 |
| Metric | LXU | LXEO |
|---|---|---|
| Price | $8.84 | $10.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $9.83 | ★ $18.90 |
| AVG Volume (30 Days) | 378.8K | ★ 1.5M |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $585,065,000.00 | N/A |
| Revenue This Year | $16.54 | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $4.88 | $1.45 |
| 52 Week High | $9.98 | $10.99 |
| Indicator | LXU | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 55.56 |
| Support Level | $8.22 | $8.93 |
| Resistance Level | $8.95 | $10.99 |
| Average True Range (ATR) | 0.24 | 0.65 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 86.30 | 58.74 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.